This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Toxic epidermal necrolysis (TEN)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Toxic epidermal necrolysis (TEN) is a rare, unpredictable, life threatening condition where there is widespread skin erythema that rapidly progresses to necrosis of the epidermidis with subsequent sloughing of skin (1,2).

There is full thickness necrosis of the epidermis which is detached from the underlying dermis.

Frequent involvement of the occular mucous membrane and oral mucous membrane can be seen (3).

Most of the cases of TEN are caused by adverse drug reactions.

It is thought to be a cell-mediated immunologic reaction against drug metabolites caused by an abnormal metabolism of the offending drugs (3).

It can be seen in all age groups presenting from infants to elderly people (4).

Stevens-Johnson syndrome and toxic epidermal necrolysis are thought to represent a single mucocutaneous disease with an increasing severity (4).

Stevens-Johnson syndrome (SJS) and TEN are differentiated by the extent of body surface involvement (3)

  • in SJS - epidermal detachment is seen in <10% of the body surface area
  • n TEN - epidermal detachment is seen in >30% of body surface area
  • overlap SJS-TEN - when detachment is between 10-30% of the body surface area (4)

Study evidence showed that antibiotics were associated with more than one-quarter of SJS/TEN cases described worldwide, and sulfonamide antibiotics remained the most important association (5)

With respect to systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome (6):

  • found when compared to corticosteroids, etanercept may result in mortality reduction
  • certainty of evidence for disease-specific mortality is very low for corticosteroids versus no corticosteroids, IVIG (intravenous immunoglobulins) versus no IVIG and cyclosporin versus IVIG

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.